PaxMedica Stock Surges on Progress Towards PAX-101 Approval for Rare Disease and Autism
• PaxMedica shares soar 125% after hours Thursday on drug update
• Completed execution of 3 registration batches of PAX-101 IV formulation
• PAX-101 targets Stage 1 Human African Trypanosomiasis (fatal tropical disease)
• Plans to file PAX-101 new drug application with FDA in Q4
• Also hopes to test PAX-101 for treating core symptoms of Autism Spectrum Disorder